{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:51:16Z","timestamp":1790373076806,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3703,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1365-2133.2005.06651.x","type":"journal-article","created":{"date-parts":[[2005,8,19]],"date-time":"2005-08-19T22:12:18Z","timestamp":1124489538000},"page":"620-625","source":"Crossref","is-referenced-by-count":120,"title":["Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus"],"prefix":"10.1093","volume":"153","author":[{"given":"M.J.","family":"Arin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hunzelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,7,12]]},"reference":[{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0735-6757(00)90124-4","article-title":"Autoimmune blistering skin diseases","volume":"18","author":"Cotell","year":"2000","journal-title":"Am J Emerg Med"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0190-9622(00)90213-5","article-title":"Patterns of remission in pemphigus vulgaris","volume":"42","author":"Herbst","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1172\/JCI119130","article-title":"Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris","volume":"99","author":"Lin","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","article-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion","volume":"67","author":"Amagai","year":"1991","journal-title":"Cell"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1523-1747.2003.12071.x","article-title":"Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies","volume":"120","author":"Leyendeckers","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0733-8635(05)70153-4","article-title":"New and emerging therapies in the treatment of blistering diseases","volume":"18","author":"Korman","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB10|cit10","first-page":"79","article-title":"The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders","volume":"27","author":"Treon","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-Lopez","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-133-4-200008150-00011","article-title":"Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease","volume":"133","author":"Ratanatharathorn","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB14|cit14","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1182\/blood.V92.9.3490","article-title":"Rituxan in the treatment of cold agglutinin disease","volume":"92","author":"Lee","year":"1998","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1365-2133.2003.05580.x","article-title":"Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab","volume":"149","author":"Goebeler","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB20|cit20","first-page":"ELT24","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case","volume":"88","author":"Virgolini","year":"2003","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1365-2133.2003.05209_10.x","article-title":"Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"148","author":"Herrmann","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jaad.2004.06.007","article-title":"Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)","volume":"51","author":"Morrison","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI117349","article-title":"Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus","volume":"94","author":"Amagai","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000024364","article-title":"Humoral and cellular autoimmunity in autoimmune bullous skin disorders","volume":"122","author":"Hertl","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/smim.1997.0080","article-title":"Regulation of B-cell commitment to plasma cells or to memory B cells","volume":"9","author":"Liu","year":"1997","journal-title":"Semin Immunol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB28|cit28","first-page":"189","article-title":"B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia","volume":"87","author":"Zaja","year":"2002","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","article-title":"T cell activation in rheumatoid synovium is B cell dependent","volume":"167","author":"Takemura","year":"2001","journal-title":"J Immunol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0952-7915(98)80162-3","article-title":"Long-lived plasma cells: a mechanism for maintaining persistent antibody production","volume":"10","author":"Slifka","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1073\/pnas.92.11.5239","article-title":"Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity","volume":"92","author":"Bhol","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2230.2003.01283.x","article-title":"Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab)","volume":"28","author":"Cooper","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06651.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1084\/jem.20022031","article-title":"The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem)","volume":"197","author":"Li","year":"2003","journal-title":"J Exp Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2005.06651.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2005.06651.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:13:11Z","timestamp":1676365991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/153\/3\/620\/6637031"}},"subtitle":["Anti-CD20 treatment in pemphigus"],"short-title":[],"issued":{"date-parts":[[2005,7,12]]},"references-count":34,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06651.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718345185.793493627","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7,12]]}}}